Stocks and Investing
Stocks and Investing
Tue, March 9, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Sumant Kulkarni Maintained (ACAD) at Strong Buy with Decreased Target to $40 on, Mar 9th, 2021
Sumant Kulkarni of Canaccord Genuity, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Strong Buy with Decreased Target from $61 to $40 on, Mar 9th, 2021.
Sumant has made no other calls on ACAD in the last 4 months.
There is 1 other peer that has a rating on ACAD. Out of the 1 peers that are also analyzing ACAD, 0 agree with Sumant's Rating of Hold.
This is the rating of the analyst that currently disagrees with Sumant
- Vamil Divan of "Mizuho" Initiated at Strong Buy and Held Target at $69 on, Wednesday, December 16th, 2020
Contributing Sources